Protagonist Therapeutics, Inc. (PTGX)
- Previous Close
24.66 - Open
24.61 - Bid 25.09 x 200
- Ask 25.16 x 200
- Day's Range
24.22 - 25.23 - 52 Week Range
13.72 - 33.34 - Volume
357,577 - Avg. Volume
661,330 - Market Cap (intraday)
1.466B - Beta (5Y Monthly) 2.05
- PE Ratio (TTM)
-- - EPS (TTM)
-1.39 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.20
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
www.protagonist-inc.comRecent News: PTGX
Performance Overview: PTGX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTGX
Valuation Measures
Market Cap
1.47B
Enterprise Value
1.13B
Trailing P/E
--
Forward P/E
13.97
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.79
Price/Book (mrq)
4.35
Enterprise Value/Revenue
18.75
Enterprise Value/EBITDA
-12.45
Financial Highlights
Profitability and Income Statement
Profit Margin
-131.59%
Return on Assets (ttm)
-19.32%
Return on Equity (ttm)
-28.59%
Revenue (ttm)
60M
Net Income Avi to Common (ttm)
-78.95M
Diluted EPS (ttm)
-1.39
Balance Sheet and Cash Flow
Total Cash (mrq)
341.62M
Total Debt/Equity (mrq)
0.34%
Levered Free Cash Flow (ttm)
-43.31M